This summary is generated by an algorithm. If you find any mistakes, let us know.

Biotechnology North America Pet Veterinary

Loyal raises $27M, aims to give dog owners more time with their pets

– San Francisco startup Loyal raised $27m in Series A funding.
– The round was led by Khosla Ventures and included First Round Capital, Box Group, Collaborative Fund, The Longevity Fund and Lachy Groom.
– The company is building an animal pharmaceutical company that is developing therapeutics aimed at extending both lifespan and healthspan for dogs.

Source
Biotechnology Health Care Medical North America Pharmaceutical

Elligo Health Research Inks $135M Series E

– Elligo Health Research, a healthcare-enabling research organization powered by the novel IntElligo technology, announced a $135m Series E financing round.
Morgan Stanley Expansion Capital and Ally Bridge Group participated in the financing round.
– The round was also participated by Norwest Venture Partners and all major existing investors, including Cerner, Hatteras Venture Partners, Noro-Moseley Partners, Piper Sandler Merchant Banking, Shumway Capital, and Syneos Health.
– This financing allows Elligo to invest further in its technology platform and leverage data in new ways to address current challenges in the clinical trial industry.

Source
Biotechnology Life Science North America Therapeutics

Garuda Therapeutics Raises $72M in Series A Financing

– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.

Source
Biotechnology Developer APIs North America Robotics

Opentrons Raises $200M in Series C Funding

– Opentrons Labworks Inc. is a NYC-based lab platform provider.
SoftBank Vision Fund 2 led the round with participation by Khosla Ventures.
– The company intends to use the funds to further invest in its automated lab platform globally.

Source
Biotechnology Clinical Trials Health Care Medical Device North America

Cryosa Announces $21.5M Series B Funding

– Medical device startup Cryosa from Singapore completed its Series B funding round, raising $21.5m.
РThe round was led by life sciences firm Solas BioVentures, with additional funding from Series A investors which include life sciences firm Sant̩ Ventures, global technology and med-tech company HOYA Corporation, and additional investors.
– The funding will be used to continue first-in-human clinical trials.

Source
Biotechnology Health Care Medical Device mHealth North America

Gramercy Extremity Orthopedics Raises $9.83 Million in Series A to Transform Orthopedics Operating Industry

– Gramercy Extremity Orthopedics raised $9.83m in Series A financing.
– The funding will be used to scale up technology infrastructure and continued product expansion with specific focus on the United States extremity market.
– The GEO CART® is an industry-first, computerized, mobile implant and instrumentation inventory system enabled with RFID technology.
– No bigger than the average medical cart, the GEO CART® system can hold over 1,000+ items tailored to the usage of a specific facility.
– The GEO CART® proprietary point-of-sale system reduces delays in surgery, decreases sterility risks to the patient, eliminates handwritten billing mistakes, automatically generates the Implant Usage Form, removes the cost to clean and sterilize instrumentation, and reduces facility operating expenses.

Source
Biotechnology Health Care North America Therapeutics

Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes

– Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome, announced that it has raised $61 million to fuel the continued development of its platform to design and develop new therapeutics mined from microbial genomes.
Nextech Invest led the financing, with participation from new investors SoftBank Vision Fund 2* and Casdin Capital, as well as existing investors The Column Group, 8VC, and Two Sigma Ventures.
– Hexagon’s interdisciplinary platform combines technological advances and proprietary insights across machine learning, genomics, synthetic biology and automation to systematically discover new chemical compounds linked to known protein targets.
– Hexagon has built a database of microbial genomes that is more than twice the size of all public databases and is adding thousands of additional genomes per month.

Source
Biotechnology Health Care Medical Device mHealth North America

Gramercy Extremity Orthopedics (GEO) Raises $9.83M in Series A Funding

– Gramercy Extremity Orthopedics (GEO) from Richardson, TX develops Orthopedic Medical Implants.
– The company raised $9.83M in Series A funding.
– The round was led by undisclosed investors.
– The new investment will be used to scale up technology infrastructure and continue product expansion with specific focus on the United States extremity market.

Source
Biotechnology Health Care Hospital Medical North America

Fauna Bio Raises $9M in Seed Funding

– Fauna Bio is an Emeryville, California-based biotechnology company leveraging animal genomics to improve human health.
– The company raised $9m in Seed funding.
– The round was led by LifeForce Capital with participation from True Ventures, Boom Capital, Pacific 8 Ventures, BioMed Ventures, Vibe Capital and Arcadia Science.
– The new investment will be used to expand its drug discovery platform Convergence while accelerating the discovery of new therapeutic targets for human diseases across a broad range of indications.

Source
Biopharma Biotechnology Health Care North America Pharmaceutical

Credence MedSystems Raises $39.9M in Funding

– Credence MedSystems, a Menlo Park, CA-based provider of drug delivery systems, raised $39.9M in funding.
– The round was led by Novartis Pharma AG and Molex Ventures LLC.
– The investment will be directed towards scaling of production capacity for the Credence Companion® and Dual Chamber Reconstitution Systems as well as development of other members of the company’s platform of innovative drug delivery systems, including its connected health portfolio.

Source
Biotechnology Health Care Life Science Medical North America Software

PhenoTips Closes CAD $2.5M Funding Round Led by GreenSky Capital for Software to Transform Medical Genetics

– PhenoTips announced that it has raised CAD $2.5m in an oversubscribed seed fundraising round led by the GreenSky Accelerator Fund IV.
– The round includes the support of the Toronto Innovation Acceleration Partners, Thin Air Labs, Yorkville Partners, and angel investors including members of the GreenSky President’s Club.
– PhenoTips empowers healthcare providers to deliver precision medicine with the most complete and interoperable software solution for medical genetics.
– The company plans to double the size of its twelve-person Canada-based team and expand its cloud-based product offerings.

Source
Biotechnology Health Care North America Pharmaceutical

858 Therapeutics Launches with Proven Team and $60 Million Series A Financing

– 858 Therapeutics has raised $60m in Series A financing.
– The round was led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital.
– 858 is a biotechnology company developing novel therapeutics for the treatment of cancer.
– The company’s lead program is a novel small molecule inhibitor of the PI3K/mTOR pathway that is being developed for the treatment of solid tumors that are resistant to existing therapies.
– The Series A proceeds will allow 858 to enter the clinic with its lead candidates that have potential to treat cancers that are resistant to current therapies.

Source
Biotechnology Manufacturing North America Textiles

3D BioFibR Inc. Raises New Capital to Scale Up Manufacturing in an Oversubscribed Round

– Aera technology announced an $80m Series C financing round bringing total investment in the company to $170m.
– Participants in this capital raise included further investments from current investors, including Concrete Ventures, as well as new investors, including Globalive Capital.
– Aera is the cognitive technology that enables the Self-Driving Enterprise™. Using data crawling, industry models, and AI, Aera automates and augments how decisions are made and executed.
– New round will accelerate Aera’s investment in its Cognitive Operating System™, Self-Driving Skills™, and global expansion to enable companies around the world to run like digital natives.

Source
Biotechnology Life Science Manufacturing North America Pharmaceutical

SmartLabs Announces $250 Million Series B and Update of Proprietary Laboratory OS

– SmartLabs, a Boston-based Laboratory-as-a-Service (LaaS) leader, announced the raise of a $250m Series B financing.
– The funding round was led by ArrowMark Partners. New investment partners include Winslow Capital Management and Onex Falcon, joined by existing investors Conversion Venture Capital (CVC2) and Breed’s Hill Capital.
– The funding will fuel the company’s accelerated growth, with a plan to scale operations to 2m sq ft within five years.
– In addition, SmartLabs announced the launch of the fourth version of its proprietary laboratory operations system (SmartLabs OS) which was first pioneered and introduced in 2016.

Source
Biotechnology Health Care Medical Pharmaceutical Therapeutics Wellness Western Europe

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Source
Biotechnology Health Care Medical Pharmaceutical Therapeutics Wellness Western Europe

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Source
Biopharma Biotechnology North America Therapeutics

Elevian Raises $40M Series A

– Elevian, an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, has raised $40m in an oversubscribed Series A round.
– The round was led by Prime Movers Lab.
– Additional investors include Bold Capital, Leslie Ventures, John A Kuelbs Family Office and others.

Source
Biotechnology North America

Othram Closes $18M Series B Funding

– Othram is a laboratory purpose-built to combine genome sequencing with advanced human identification applications, raised an $18m Series B funding round.
– The round was led by Gigafund.
– The company intends to use the funds to further develop the breakthrough technology that is helping investigators crack these unsolved cases.

Source
Biotechnology Eastern Asia Pharmaceutical

IASO Biotherapeutics Secures $108 Million Series C Funding to Advance Global Development of Innovative Cell Therapies

– IASO Biotherapeutics announced the completion of $108m Series C to advance the global development of novel cell therapies and biologics for oncology and autoimmune diseases.
– The round was led by CDH Baifu, and followed by CCB International, with strong participation from Everbright Limited, Co-Stone Capital, CNCB Capital and Plaisance Capital.
– Current shareholder GL Ventures also participated.
– Since its founding in 2017, IASO Bio has raised more than $178m.
– Proceeds from the financing will be used to accelerate the global development and regulatory submissions of multiple novel cell therapies.

Source
Biotechnology Genetics Health Care Life Science North America

African genomics startup 54gene raises $25M to expand precision medicine capabilities

– African genomics startup 54gene has raised $25m in Series B funding.
– Pan-African venture capital firm Cathay AfricInvest Innovation Fund led this round.
– Lead investor from the company’s Series A funding, Adjuvant Capital, invested once again with participation from other VCs including KdT Ventures, Plexo Capital, Endeavor Catalyst and Ingressive Capital.
– The company has raised a total of $45m since its inception.

Source
Biopharma Biotechnology Health Care Medical North America

Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures

– Aptinyx Inc. has entered into a $50m loan facility and security agreement with K2 HealthVentures.
– The funds will provide general growth capital as Aptinyx advances its late-stage clinical pipeline of novel NMDA modulators.
– Under the terms of the agreement, the remaining $25m is subject to the achievement of certain terms and conditions, including regulatory and developmental milestones.

Source
Biotechnology Health Care Medical North America

Alpine raises $91M to fuel the Seattle biotech’s clinical trials for lupus and cancer

– Alpine Immune Sciences, a publicly traded biotech, raised $91m in funding.
– The funding will support the company’s ongoing trials for cancer and a potential treatment for immune conditions.
– The company plans to initiate a phase 1 study for the agent by this winter.

Source
Biotechnology Medical North America Therapeutics

Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform

– Allay Therapeutics completed its oversubscribed $60M Series C financing, led by Arboretum Ventures.
– The proceeds from the Series C will advance the Company’s lead candidate, ATX-101, into Phase 2b clinical trials, and support the further development of Allay’s platform for ultra-sustained analgesic products.
– Allay intends to proceed into a Phase 2b study of ATX-101 in total knee arthroplasties (TKA, also called total knee replacements) in the United States.

Source
Biotechnology Pharmaceutical Western Europe

Anjarium Biosciences Raises $61M in Series A Financing

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Source
Biotechnology Pharmaceutical Western Europe

Anjarium Biosciences Raises $61M in Series A Financing

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Source
Agriculture AgTech Biotechnology GreenTech North America Sustainability

Andes Raises USD 15 Million in Series A Funding Co-Led by Leaps by Bayer and Cavallo Ventures

– Bayer’s impact investment arm Leaps has co-led a USD 15m Series A investment round in agriculture and biotechnology innovator, Andes.
– Other new investors Builders VC, Germin8, Accelr8 and Wilson Sonsini participated, alongside existing investors KdT Ventures and Endurance.
– Through its novel seed treatment technology, called ‘Microprime’, Andes is reducing the need for synthetic fertilizers.
– The California-based company has developed a process for seamlessly integrating seeds with a unique library of microbes that colonize the seed’s root structure. This kick-starts a process known as biological nitrogen fixation, enabling the crop to draw down nitrogen from the air instead of relying on synthetic nitrogen fertilizers.

Source
Biopharma Biotechnology Therapeutics Western Europe

TreeFrog Therapeutics Raises $75M In Series B Financing

– TreeFrog Therapeutics, a Bordeaux, France-based biotech startup focused on developing stem cell-derived cell therapies for millions of patients, closed a $75m (€64M) Series B financing round, bringing the total funding to date to $83m (€70m).
– The round was led by Bpifrance Large Venture, part of the French Public Investment Bank, joined by U.S. investment firm Leonard Green & Partners L.P., global pharmaceutical company Bristol Myers Squibb, and European venture capital team XAnge.
– The company intends to use the funds to deploy biomimetic C-StemTM technology for clinical-grade manufacturing, grow and advance to the clinic a comprehensive pipeline of cell therapies, and finance the opening of technological hubs in Boston, MA, and Kobe, Japan.

Source
Biotechnology Health Care North America Pharmaceutical

ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform

– ROME Therapeutics announced the completion of a $77m Series B financing round.
– The round was led by new investor Section 32 and included participation from Sanofi Ventures, Casdin Capital, Andreessen Horowitz and Alexandria Venture Investments.
– ROME’s mission is to harness the power of the repeatome – the roughly 60% of the human genome consisting of repetitive sequences of nucleic acids, known as repeats – to discover powerful new classes of medicines for cancer and autoimmune diseases.
– ROME has identified multiple repeatome-derived targets and created an internal data science platform, called repeatomics, to analyze vast quantities of data available through the repeatome.

Source
Agriculture Biotechnology North America Service Industry

AgBiome Raises $116 Million Led By Blue Horizon and Novalis LifeSciences

– AgBiome raised $116m in an oversubscribed Series D round of funding.
– The round was co-led by Blue Horizon and Novalis LifeSciences and included multiple new and existing investors.
– The company will use the capital to expand more rapidly its product portfolio, scale its scientific and commercial teams, and continue to build its global presence and partnerships.

Source
Biotechnology Life Science North America

Walking Fish Therapeutics Launches with $50 Million in Series A Financing to Accelerate Development of B Cell Therapies for Multiple Diseases

– Walking Fish Therapeutics, a leader in B cell engineering, announced the close of $50M Series A financing— led by Emerson Collective, Illumina Ventures and Quan Capital— to develop B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production.
– Walking Fish Therapeutics has made critical advances in developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies.

Source
Biotechnology Genetics Health Diagnostics Life Science North America

Mammoth Biosciences Raises $195 Million to Build Next-Generation CRISPR Products in Therapeutics and Diagnostics

– Mammoth Biosciences has secured $195m in financing, joining the select ranks of “unicorn” startups with a valuation of more than $1bn.
– The funds will enable the company to broaden its toolkit of next-generation CRISPR systems with a focus on building permanent genetic cures through in vivo gene-editing therapeutics and democratizing disease detection with on-demand diagnostics.
– Mammoth’s CRISPR platform leverages the largest toolbox of novel Cas enzymes, driven by its proprietary protein discovery engine which leverages the natural diversity of life.

Source
Biotechnology Health Care Health Diagnostics Medical Device North America

Seattle startup RareCyte raises $24M to advance new high-speed cell imaging platform

– Seattle-based startup RareCyte announced $24m in new funding.
– The funding will fuel the commercialization and development of its new Orion cell imaging and analysis platform, launched last year.
– The company markets kits for preparing samples from blood or tissues and instruments to optically measure cells.
– Their products aim for automation and high-volume of sampling.

Source
Biotechnology Life Science Southeast Asia

Digital therapeutics startup Neuroglee raises $10M to help people with neurodegenerative conditions

– Neuroglee Therapeutics, a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10m Series A led by Openspace Ventures and EDBI.
– The funding will be used to launch virtual neurology clinics and to support Neuroglee’s move to Boston.
– Other participants included Ramen Singh, the former chief executive officer of Mundipharma; Biofourmis co-founders Kuldeep Singh Rajput and Wendou Liu; and Eisai, the Japanese pharmaceutical that led Neuroglee’s last round last year.
– Neuroglee’s adaptive learning tech uses machine learning and biomarkers related to cognitive function, mood and behavior to automatically personalize therapy plans for each patient, who access the software through a smartphone or tablet.

Source
Biotechnology Energy North America Oil and Gas

Calysta Raises $39M in Series D-1 Funding

– Calysta is a San Mateo CA-based biotechnology company focused on alternative protein producer.
– The company raised $39M in Series D-1 funding.
– The round was led by bp ventures with participation from were Adisseo, AquaSpark and WTI, as well as other existing investors.
– The new investment will be used to support global scale-up of production of its FeedKind protein.

Source
Biotechnology Health Care North America Pharmaceutical

Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.

Source
Biotechnology Health Care Western Europe

PetMedix Raises $37M in Series B Funding

– PetMedix, a Cambridge UK-based animal health company, raised $37M in Series B funding.
– The round was led by Tencent and Kyoritsu Holdings with participation from Digitalis Ventures, Parkwalk Advisors and Cambridge Innovation Capital.
– The company intends to use the funds to advance its innovative pipeline through clinical development.

Source
Biotechnology Life Science North America Therapeutics

Via Nova Therapeutics Raises $20M in Series A Financing

– Via Nova Therapeutics is an Oakland, Calif.-based company established to discover and develop therapeutics for acute and subacute viral infections.
– The company closed raised $20m in Series A financing.
Aditum Bio made the investment.
– The new investment will be used to advance the development of four preclinical antiviral programs in-licensed from Novartis.

Source
Biotechnology Health Care Health Diagnostics North America

YourBio Health Raises $21M in Funding

– YourBio Health from Boston develops a personal health information company, raised $21M in funding.
– Series A round was led by Flagship Pioneering with participation from Newpath Partners.
– The company intends to use the funds to accelerate growth and support forthcoming product launches.

Source
Biopharma Biotechnology GreenTech Manufacturing North America

Solugen Raises Over $350 Million in Series C Funding Led by Baillie Gifford & GIC to Make Carbon Negative Chemicals

– Solugen, the company decarbonizing the chemicals industry, announced a Series C financing round of over $350m.
GIC and Baillie Gifford led the round with participation from Temasek Holdings.
– The latest round of funding will be used to expand Solugen’s Bioforge technology platform, which is used to produce lower-carbon and carbon-negative chemicals & materials for its key customers, and to expand the reach of Solugen’s product portfolio.

Source
Biotechnology Health Care North America Product Design

University of Washington spinout A-Alpha Bio snags $20M for protein-discovery platform

– A-Alpha Bio, a drug development platform company, raised $20m funding.
– The funding was led by Seattle’s Madrona Venture Group and joined by other investors.
– The company plans to build lab space in downtown Seattle and beef up its machine learning team with the funding.
– The company uses information from its datasets to train its algorithms to predict favorable protein interactions.

Source
Australia and Oceania Biotechnology Health Care Life Science Medical

HaemaLogiX Raises $10M in Funding

– haemaLogiX from Sydney is a biotech company developing a drug to treat a rare blood disorder.
– The company raised $10M in Series A funding.
– The round was led by Platinum Asset Management via its Platinum International Health Care Fund.
– The investment will be used to support the manufacturing of the next batch of the Kappa antibody plus the conduct of a higher dose, 30mg/kg, monotherapy study and prepare for two further studies.

Source
Biotechnology Health Care Medical North America Pharmaceutical

ADARx Raises $75 Million to Advance Growing Pipeline

– ADARx Pharmaceuticals, Inc. completed a $75m Series B financing.
– The round was co-led by SR One Capital Management and OrbiMed Advisors.
Sirona Capital joined this financing as well as existing investor Lilly Asia Ventures.
– The proceeds from the Series B financing will be used to advance ADARx’s proprietary RNA platform technologies for base editing, inhibition, degradation, and delivery.
– The proceeds will also be used to transition ADARx’s growing pipeline of research phase products into the clinic including initiation of a Phase 1 clinical trial for ADARx’s lead program.

Source
Biotechnology Genetics Health Diagnostics North America Pharmaceutical

bluebird bio Secures $75 Million in Private Placement Equity Financing

– bluebird bio, Inc. announced that it has entered into an agreement for a $75m private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process.
– Proceeds from the financing will support ongoing R&D and commercialization investments for bluebird bio and for 2seventy bio, which plan to launch as independent companies in October 2021.
– bluebird plans to complete the spin-off of 2seventy in October 2021, subject to customary conditions, including effectiveness of the Form 10, a favorable opinion from the IRS with respect to the tax-free nature of the transaction, and final approval from bluebird’s Board of Directors.

Source
Biotechnology North America

HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Source
Biotechnology Health Care Life Science Medical North America

Emulate Closes $82 Million Series E Financing to Scale Amid Rapid Growth in Organ-on-a-Chip Market

– Emulate, Inc. announced the close of an $82m Series E financing round.
– The round was led by Northpond Ventures with additional participation from Perceptive Advisors.
– With this investment, Emulate has raised nearly $225m to date.
– Emulate develops and manufactures next-generation in vitro models that enable researchers to replicate and study human biology and disease, helping them understand and predict drug response with greater precision and detail than possible with conventional cell culture or animal-based methods.
– Organ-on-a-chip technology by Emulate provides flexible microenvironments containing tiny hollow channels lined with living cells and tissues that can be subjected to mechanical forces that mirror breathing or digestion in the human body.

Source
Biotechnology Clinical Trials Life Science Western Europe

EnteroBiotix Raises $21M in Series A Funding

– EnteroBiotix is a biopharmaceutical company based in Glasgow, Scotland.
– The company raised $21m in Series A funding.
– The round was led by Thairm Bio with participation from Kineticos Ventures, Scottish Enterprise and SIS Ventures.
– The new investment will be used to advance the company’s microbiome drug pipeline and product development and manufacturing capabilities and grow its headcount to around 50.

Source
Biotechnology Life Science Western Europe

ILC Therapeutics Announces Successful Completion of £3.5m Funding Round

– ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of interferon drugs, announces the successful completion of a £3.5m funding round.
– Investors include Los Angeles-based lawyer and investor, Robert Kopple; St Andrews-based Eos Angel Investment Syndicate; Scottish Enterprise; ILCT management.
– Chairman Peter Bains said: “We are very pleased to complete this important funding round and to strengthen the Board with the appointment of Robert Kopple, Professor David Harrison and Chris Brinsmead. With this funding in place, ILCT is now well positioned to strengthen its novel technology platform and to advance its lead candidate, Alfacyte™ through IND enabling studies in preparation for clinical trials as an anti-viral therapeutic for Covid 19.

Source
Biotechnology Medical Device Western Europe

Locate Bio Closes £10 Million Funding Round

– Locate Bio is pleased to announce that it has raised an oversubscribed £10 million of equity investment in a funding round co-led by existing shareholder Mercia Asset Management and new investor BGF.
– The funding will be used to further advance Locate Bio’s proprietary pipeline of regenerative orthobiologics products towards patients, with key clinical and regulatory milestones expected to catalyse growth over the next two years.
– The investment brings the total funds raised by Locate Bio to over £18 million. The company’s lead product in development is called LDGraft, and is a low dose, controlled release rhBMP-2 for the treatment of degenerative disc disease.

Source
Biotechnology Health Care Medical North America

Disc Medicine Raises $90M in Series B Funding

– Disc Medicine from Cambridge MA develops therapeutic candidates for hematology.
– Series B $90M round was led by OrbiMed and attracted new investor – Arix Bioscience as well as existing investors Atlas Venture, Novo Holdings and Access Biotechnology.
– The new investment will be aimed at developing the company’s hematology pipeline of therapeutic candidates.

Source
Biotechnology North America Therapeutics

Asher Bio Closes $108 Million Series B Financing

– Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the closing of an oversubscribed Series B financing, which raised $108m.
– The financing was led by Wellington Management Company, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace and Alexandria Venture Investments, and, along with existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and other undisclosed institutional investors.

Source
Biotechnology Health Care Medical North America

HebeCell Raises $53 Million in Series A Financing to Advance Unique Off-The-Shelf PSC-CAR-NK Products Into Clinics

– HebeCell has successfully closed a US$53m Series A financing to advance its unique off-the-shelf pluripotent stem cell (PSC)-CAR-NK products into clinics.
– This strategic investment is led by Jacobio Pharmaceuticals, who will collaborate with HebeCell to develop the next-generation PSC-CAR-NK therapy for cancer, viral infection, and autoimmune diseases.
– Capital from this financing will be used to accelerate HebeCell’s R&D program, IND filing, clinical application, and marketing as the company grows its operations both in the US domestically and internationally. It will also help HebeCell expand globally and gain international presence in the NK cell therapy industry.

Source
Biotechnology Life Science Medical North America Pharmaceutical

Versanis Bio Raises $70M in Series A Financing

– Versanis Bio is an Oakland, Calif.-based company established to discover and develop first-in-class medicines that address medical conditions prevalent in older adults.
– The company closed a $70m Series A financing.
– The round was co-led by Atlas Venture and Medicxi with participation from Aditum Bio.
– The company intends to use the funds to advance a comprehensive phase 2 clinical program to evaluate the potential of bimagrumab to help obese patients lose fat and achieve an improved body composition.

Source
Biotechnology Health Care Medical Device Western Europe

Tissium Raises €50M in Series C Financing

– Tissium is a medtech company developing biomorphic programmable polymers for tissue reconstruction.
– Company raised €50M in Series C financing.
– The round was led by Cathay Health, affiliated to global investment firm Cathay Capital, with participation from existing shareholders Sofinnova Partners, and others.
– The company intends to use the funds to continue to execute on its development plan, up to the commercialization of its nerve repair, hernia repair and cardiovascular sealant products.

Source
Biotechnology Consumer North America Product Search

Triad Life Sciences Closes A$25M Funding

– Triad Life Sciences, a Memphis, Tenn.-based biotech company, raised AUS$25m funding round.
– The convertible note placement was led by Cannacord Genuity.
– The company intends to use the funds for its US sales force expansion plans, R&D activities, and general working capital needs.

Source
Biotechnology North America

Laronde Raises $440M in Series B Financing

– Laronde is a Cambridge, Mass.-based company advancing Endless RNA™ (eRNA) – a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body.
– The company raised $440m in Series B financing.
– The round was led by Flagship Pioneering, with participation from T. Rowe Price Associates, Inc., Invus, Canada Pension Plan Investment Board (CPP Investments), Fidelity Management & Research Company, funds and accounts managed by BlackRock, and Federated Hermes Kaufmann Funds, among others.
– The new investment will be used to advance the development of the company’s eRNA platform and a broad pipeline of programs across a number of therapeutic categories.

Source
Biotechnology Eastern Asia Health Care Pharmaceutical

Lynk Pharmaceuticals Closes $50M Series B Financing

– Lynk Pharmaceuticals is a Hangzhou, China-based pharmaceutical R&D company.
– The company completed Series B financing of $50m.
– The round was led by Lilly Asia Ventures (LAV) with participation from New Alliance Capital and Hangzhou HEDA Biological Medicine Venture Capital Partnership (L.L.P.) and its original shareholders Legend Capital and Med-Fine Capital.
– The new investment will be used to conduct Phase I and II clinical trials for multiple programs in the R&D pipeline, expand international business, strengthen international collaborations with companies and support preclinical development of new projects.

Source
1 2 3 6 7 8
Crunchbase icon

Content report

The following text will be sent to our editors: